Posted by Michael Wonder on 25 Oct 2021
Roche’s Ventana PD-L1 (SP263) assay receives FDA approval as a companion diagnostic to identify certain non-small-cell lung cancer patients eligible for Tecentriq (atezolizumab)
22 October 2021 - The Ventana PD-L1 (SP263) assay helps determine which non-small-cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase 3 IMpower010 trial.
Roche today announced U.S. FDA approval of the Ventana PD-L1 (SP263) assay in non-small-cell lung cancer as a companion diagnostic test for Tecentriq, advancing the company's commitment to guide clinical decision making through innovative, high quality assays that improve patient access to personalised health care.
